ophthalmic examination. On examination, visual acuity was 20/30 in the OD and 20/80 in the OS. A pigmented, vascularized, bulbous mass was seen in the 11: 00-2: 00 position of the left iris with hemorrhage into the iris stroma ( fig. 1 a) . B-scan ultrasound showed a mass with heterogeneous reflectivity causing lens subluxation ( fig. 1 b) . Intraocular pressure measured 26 mm Hg in the left eye, but the trabecular meshwork was open on gonioscopy. The patient was given the clinical diagnosis of ciliary body melanoma. Due to the presumed diagnosis as well as the patient's increasing pain and intraocular pressure, he was prescribed 0.1% dexamethasone eye drops 4 times daily, 1% cyclopentolate twice daily, slow-release acetazolamide 250 mg by mouth once daily, and was referred to the Ocular Oncology Service of the St. Bartholomew's Hospital (London, UK). Various treatment options were discussed, including observation, but the patient opted for enucleation. The postoperative course was uneventful. Punch biopsy using a corneal trephine as well as fine needle aspiration (FNA) biopsies of the mass were obtained and sent for cytogenetic testing for chromosomes 3 and 8 (prognostic markers in uveal melanoma routinely tested at our center) [6] . The remainder of the specimen was preserved in 10% formalin and submitted for histological processing.
Pathology
Macroscopic examination showed a pale grey translucent gelatinous nodule in the ciliary body measuring 12 × 8 mm in size.
Microscopic examination revealed a mass arising from the anterior ciliary body epithelium, consisting of neuroepithelial cells forming cords, trabeculae and rosette-like structures reminiscent of primitive neural tube ( fig. 2 a, b) . Part of the mass was adherent to the posterior iris. Normal mitoses were seen. The copious background stroma was made up of Alcian blue-positive, hyaluronidase-sensitive material. Immunohistochemistry showed weak diffuse positivity for chromogranin but was negative for synaptophysin staining. S100 showed patchy strong positivity. The remaining immunohistochemistry for AE1/AE3, CAM5.2, CK7, CK20, and EMA demonstrated focal positivity. Interphase fluorescence in situ hybridization (FISH) analysis was carried out using IGH/MYC, CEP8 tri-color dual fusion probe, CEP3 (D3Z1) SpectrumOrange probe, and CEP8 (D8Z2) SpectrumGreen probe (Abbott Molecular, Des Plaines, Ill., USA). FISH analysis of the punch biopsy showed an extra copy of the chromosome 3 centromere, indicative of trisomy 3 in 50 of 100 cells examined and the normal diploid component of the chromosome 8 centromere in 100 of 100 cells ( fig. 2 c) . Interphase FISH analysis of the fine needle aspiration biopsy showed an extra copy of the chromosome 3 centromere, indicative of trisomy 3, and an extra copy of chromosome 8 centromere and MYC (8q24), indicative of trisomy 8 in 38 and 34 of 100 examined cells, respectively ( fig. 2 d) .
Discussion
These histological findings are consistent with a nonteratoid medulloepithelioma. Though experimental tumors have been created from ciliary body stem cells, in general, the term medulloepithelioma is reserved for embryonic neoplasms believed to arise from embryonal or fetal tissues, making 'embryonal medulloepithelioma' redundant and 'adult medulloepithelioma' contradictory [5] [6] [7] . At least 16 cases of medulloepithelioma have been reported in patients older than 20 years, with the oldest in a 79-year-old man [9, 10] . We documented another male whose congenital tumor became symptomatic in his 7th decade of life. Thus far, it has not behaved in an overtly aggressive or malignant manner (local invasion, metastasis, etc.). This is the first time that cytogenetic testing has been performed on an intraocular medulloepithelioma in an elderly adult.
The cytogenetics of medulloepithelioma are only recently beginning to be elucidated, with many genetic alterations including abnormalities in chromosomes 1, 4, 6, 8, 15, and 16 [11] [12] [13] . In two large series, Korshunov et al. [13] have recently proved that intraocular medulloepitheliomas and embryonal tumors of the central nervous system with multilayered rosettes are distinct nosologic entities, and Sahm et al. [14] found a high prevalence of DICER1 and KMT2D somatic mutations. Both the punch and FNA biopsies of our tumor showed trisomy of chromosome 3, which was rare in those series. All cells in the punch biopsy showed the normal diploid component of the chromosome 8 centromere and MYC (8q24), but some of the cells in our FNA biopsy contained trisomy of chromosome 8. Gain of chromosome 8 was common in those series. Intratumor genetic heterogeneity has not been previously documented in medulloepithelioma.
Medulloepithelioma of the ciliary body has been primarily diagnosed by FNA biopsy and cytology on two occasions. One was a pediatric case (8 years of age), which could not be conclusively differentiated from retinoblastoma, and the other was a 23-year-old case, who required a secondary tissue biopsy for a definitive diagnosis [14, 15] . Besides the inconsistencies in diagnosis, FNA and tissue biopsy of malignancies carry a risk of systemic dissemination. Though systemic chemotherapy with a combination of vincristine, carboplatin, and etoposide has been successful in treating an aggressive medulloepithelioma with extraocular extension and metastasis, there is no standardized treatment regimen and the chemosensitivity in this case cannot be generalized to all types of medulloepithelioma [16, 17] . Plaque brachytherapy has shown promise in inducing tumor regression in a small British case series of pediatric medulloepithelioma and in an adult case reported by Poon et al. [18] . In atypical presentations, primary enucleation remains a useful diagnostic and therapeutic tool, and should be considered in these cases. In conclusion, intraocular medulloepitheliomas are often initially misdiagnosed. Though commonly believed to be congenital, they may exhibit rapid growth, contain chromosomal abnormalities, and must be considered in all age groups.
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